DUXAP8 and hepatocellular carcinoma: The knockdown of DUXAP8 enhanced the chemosensitivity of HCC cells to sorafenib, while its overexpression reduced the chemosensitivity of HCC cells to sorafenib, and both results could be reversed by the overexpression and knockdown of MAPK1, respectively (Supplementary Figure S6).